Todd Druley, Sandra Close, Karen Fritschen
ArcherDx has appointed Todd Druley as the firm's chief medical officer, Sandra Close as the senior VP of regulatory and diagnostic strategy, and Karen Fritschen as VP of human resources.
Prior to joining ArcherDx, Druley previously recently served as an associate professor of pediatrics, hematology, and oncology at Washington University of Medicine in St. Louis. He is an inductee into the American Society of Clinical Investigators and serves as a scientific advisor for Alex's Lemonade Stand Foundation, the Gateway Chapter of the Leukemia & Lymphoma Society, the Kids Shouldn't Have Cancer Foundation, the B+ Foundation, and the Eli Seth Matthews Leukemia Foundation. Druley will continue to see children with cancer predisposition as well as oversee his academic research lab at WUSTL.
Before joining ArcherDx, Close served as CEO of GenEngine. In addition she was responsible for building the health outcomes function for Baxter Healthcare/Caremark. She also lead the research and biomarker functions, including personalized medicine and companion diagnostics at Eli Lilly. Close also previously served as Arrogen's chief scientific officer.
Colin McCracken
Colin McCracken has joined Fluidigm as chief commercial officer. Prior to joining Fluidigm McCracken was VP of chromatography and mass spectrometry, EMEA, for Thermo Fisher Scientific. He also previously led commercial operations in Europe for Invitrogen and Life Technologies, and has worked with Bristol-Myers Squibb.
Kathleen Sebelius
Exact Sciences has appointed Kathleen Sebelius to serve as a director on its board. She will sit on the firm's corporate governance and nominating committee and on its innovation, technology and pipeline committee. Sebelius currently serves as CEO of Sebelius Resources, a strategic consulting firm that advises private companies, non-profit organizations, and financial investors. From April 2009 through June 2014, she served as the Health and Human Services Secretary for President Barack Obama. She also served as Governor of Kansas from 2003 to 2009, and her previous elected offices include two terms as the Kansas insurance commissioner and four terms in the Kansas legislature.
Sebelius currently sits on the boards of biopharmaceutical companies Dermira and Myovant Sciences, as well as the Kaiser Family Foundation. She also co-chairs the Aspen Institute Health Strategy Group and serves on advisory boards for the Dole Institute of Politics, Solera Health, Out Leadership, the Estée Lauder Foundation, and the University of Kansas College of Liberal Arts and Sciences.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.